INAB
IN8bio Inc

1,778
Mkt Cap
$19.69M
Volume
254,382.00
52W High
$7.20
52W Low
$1.17
PE Ratio
-0.44
INAB Fundamentals
Price
$2.00
Prev Close
$1.72
Open
$1.70
50D MA
$1.95
Beta
1.09
Avg. Volume
40,078.40
EPS (Annual)
-$4.44
P/B
0.71
Rev/Employee
$0.00
$14.07
Loading...
Loading...

Earnings Recap

IN8bio Inc's existing cash of $27.1M as of December 31, 2025, is projected to fund operating expenses and capital expenditure requirements only through April 2027, raising substantial doubt about the company's ability to continue as a going concern.

Bullish

IN8bio Inc's INB-100 trial showed 100% relapse-free survival in AML patients, while INB-200/400 trials demonstrated improved survival in GBM. The company's INB-619 TCE also exhibited strong preclinical efficacy and a favorable safety profile.

Bearish

IN8bio Inc faces substantial doubt as a going concern with limited cash runway, significant clinical development and regulatory uncertainties for its early-stage candidates, and complex manufacturing and supply chain dependencies.

Latest INAB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.